In this article, we will look at the 12 Most Oversold Healthcare Stocks to Buy Now.
Are Healthcare Costs Rising in the US?
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022. The healthcare sector accounted for around 17.6% of the US economy in 2023, reflecting a 17.4% rise from 2022. The two primary drivers of this growth are the rise in private health insurance and Medicare.
READ ALSO: 10 Best Performing Healthcare Stocks So Far in 2025 and 10 Most Undervalued Small-Cap Stocks To Invest In.
What Could Trump’s Tariffs Mean for the Healthcare Industry
Since more and more companies in the US are looking towards China for deals regarding the next promising molecule, whether in the obesity or cancer space, the impact of tariffs on this ongoing trend has become a subject of significant discussion in the healthcare industry. On February 7, Carlo Rizzuto, Versant Ventures managing director, appeared on CNBC’s ‘Fast Money’ to discuss the impact of tariffs on healthcare. Rizzuto believed that there are two ways in which tariffs could impact the industry. The first would be products innovated in China and brought over to the US or other markets. To understand how the tariffs would affect such trade processes, the industry would have to see how the tariffs are actually structured in the market.
Secondly and more tangibly, China is a massive center for contract research and manufacturing for the US healthcare industry. Therefore, anything that increases that cost is likely to make the market conditions more challenging. The healthcare industry is already under pressure in terms of investor sentiment, and an increase in cost is not going to help its functioning.
China and the US Healthcare Sector: What’s the Connection?
Talking about the immense role played by China in the pharma and healthcare space, Rizzuto said that a significant majority of healthcare companies are using a Chinese CRO or manufacturing partner in some way in the R&D process. It is thus a very significant part of how biotech or pharma companies operate in the country. This trend is widely prevalent, going from the smallest companies to the largest.
Simply speaking, it is not possible for healthcare companies to reshore all of the externalized R&D and manufacturing to the US, as the country does not have enough capacity to accommodate the transfer. It is thus very difficult to imagine how a reshoring of such magnitude could take place. The costs to undertake this feat can be calculated linearly with the amount of tariffs applied.
Delving deeper into the industry dynamics, Rizzuto termed the obesity space and, more broadly, the cardiometabolic domain as the single largest value-creation opportunity in the industry’s history. In a recently published article on 10 Best Drug Stocks to Buy Now, we discussed whether China is the next big thing in the pharmaceutical industry. Here is an excerpt from the article:
“Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for medicines in China. According to data from DealForma, as reported by CNBC, around 30% of Big Pharma deals with at least $50 million upfront in 2024 included Chinese companies. This was up from 20% the year before and almost 0% only five years prior. The surge in China deals is materializing when US policymakers and President Donald Trump are pursuing protectionist policies in technology, such as semiconductors and AI.
Various reasons are being attributed to this trend. Experts believe that Chinese companies are developing more effective molecules than ever before, that too in large quantities. They are in a position to begin testing these molecules on human subjects quicker and at a lower price than the US. Buyers have devised a business model allowing them to essentially import the medicines through licensing deals, according to CNBC. Biotech companies are further pushed into making these deals due to the drying up of venture funding in China.
Despite varying opinions among experts, there is an industry-wide consensus that this unique trend is here to stay. How this trend might affect the US biotech sector remains unclear at the moment. While some people believe it could potentially ruin American startups if large pharmaceutical companies stumble upon a promising Chinese drug at low price, others believe the competition would be fruitful for the industry. Either way, this trend is anticipated to metamorphose the landscape of the American biopharma sector”.
With these trends in view, let’s look at the 12 most oversold healthcare stocks to buy now.
A healthcare professional in full protective gear performing a medical procedure.
Our Methodology
We used stock screeners to compile a list of healthcare stocks that experienced significant declines over the past year. We then selected the 12 stocks with the highest analyst upside potential. We also added the number of hedge fund holders for these stocks, as of Q3 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside potential. All data is as of February 18, 2025.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
12 Most Oversold Healthcare Stocks to Buy Now
12. Novo Nordisk A/S (NYSE:NVO)
Year Perf: -33.70%
Analyst Upside: 49.25%
Number of Hedge Fund Holders: 61
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. Novo Nordisk A/S (NYSE:NVO) is one of the two major pharmaceutical companies competing in the GLP-1 weight loss market, with the other being Eli Lilly.
While both companies have approved weight loss medicines leading the market with billions in revenue, Novo Nordisk A/S (NYSE:NVO) is working on a new oral weight loss pill that may transform the market if approved. Novo Nordisk CEO Lars Fruergaard Jørgensen said the company plans to file for regulatory approval for its oral weight loss drug in the United States in the coming months. If the company gains approval, it may be able to launch the drug as early as next year, which is when Eli Lilly also plans the release of its weight loss drug.
Apart from potential optimism surrounding this oral weight loss drug, Novo Nordisk A/S (NYSE:NVO) is functioning on strong fundamentals. Fiscal 2024 was a strong year for the company, with sales climbing 25% to $40.6 billion. It also raised its total dividend per share by 21.3% to DKK 11.40, which includes an interim dividend of DKK 3.50 distributed in August. This is the 29th consecutive year of dividend growth at NVO. In 2025, Novo Nordisk A/S (NYSE:NVO) expects a free cash flow of around DKK 75 to 85 billion and sales growth of 16-24% at constant exchange rates.
11. Acadia Healthcare Company, Inc. (NASDAQ:ACHC)
Year Perf: -49.70%
Analyst Upside: 56.48%
Number of Hedge Fund Holders: 43
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US in various settings, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics.
The company reported strong fiscal Q3 2024 results, with a total revenue of $816 million, reflecting growth of 8.7% over fiscal Q3 2023. This growth was attributed to patient day growth and rate improvement. Same facility revenue also grew by 8.6% compared to the same quarter last year, including patient day growth of 4.7% and an increase in revenue per patient day of 3.6%. In addition, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) reported a 10.5% increase in adjusted EBITDA for fiscal Q3 2024 compared to the same quarter in the previous year. In addition, adjusted EBITDA margin was 23.8% compared with 23.4% for the same quarter last year, an expansion of 40 basis points.
Apart from its solid financials, the company is progressing consistently across its bed growth targets. It is on track to complete the construction of around 1,200 beds this year, including nearly 700 beds in fiscal Q4 from several new joint ventures and wholly owned facilities. It is also on track to add over 400 beds to its existing facilities for the year, including over 300 expected in fiscal Q4 2024. The company ranks 11th on our list of the 12 most oversold healthcare stocks to buy now.
Aristotle Small Cap Equity Strategy stated the following regarding Acadia Healthcare Company, Inc. (NASDAQ:ACHC) in its Q4 2024 investor letter:
“Acadia Healthcare Company, Inc. (NASDAQ:ACHC), a behavioral healthcare and substance abuse treatment services company, continues to be impacted by the negative sentiment surrounding the news headlines related to patient care and questions about billing practices. While we take these developments seriously, we believe investors’ reaction to the news has been more severe than warranted. Industry peers have faced similar levels of scrutiny in the past with limited fundamental impact, and unless additional information is uncovered, we believe the current scrutiny will be resolved without much of an impact on their business. We continue to believe the company is well positioned to be an important part of the solution to an unfortunately growing need for behavioral health services.”
10. CRISPR Therapeutics AG (NASDAQ:CRSP)
Year Perf: -34.11%
Analyst Upside: 57.33%
Number of Hedge Fund Holders: 27
Headquartered in Zug, Switzerland, CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform. The CRISPR/Cas9 platform allows precise changes to genomic DNA by employing gene editing technology. The company’s product portfolio spans therapeutic programs across various disease areas, including oncology, rare diseases, regenerative medicine, etc.
CRISPR Therapeutics AG (NASDAQ:CRSP) is focusing on strategically advancing its portfolio of clinical trials across autoimmune, diabetes, oncology, and cardiovascular indications. The FDA approval and launch of CASGEVY, a gene therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older, have created considerable momentum for the company. CRISPR Therapeutics AG (NASDAQ:CRSP) has also received regulatory approval for the drug in various countries across the globe, including Canada, Switzerland, Great Britain, the European Union, and others, with product launches underway. The ongoing launch of the drug is continually gaining momentum, with new cell patient collection initiations expected to grow significantly in 2025. More than 50 authorized treatment centers (ATCs) have been activated globally for CASGEVY.
As of December 31, 2024, it has a strong balance sheet with around $1.9 billion in cash, cash equivalents, and marketable securities. Thus, supported by an approved commercial product, a strong balance sheet, and a rich pipeline, it is in a suitable position to expand its operations in 2025 and beyond.
9. Elanco Animal Health Incorporated (NYSE:ELAN)
Year Perf: -30.26%
Analyst Upside: 60.64%
Number of Hedge Fund Holders: 42
Elanco Animal Health Incorporated (NYSE:ELAN) is an animal health company that delivers services and products that prevent and treat disease in pets and farm animals. Its diverse portfolio serves animals across various species, primarily cats, dogs, cattle, swine, poultry, and sheep.
The company’s product offerings are divided into Farm Animal and Pet Health. The Pet Health portfolio specializes in parasiticides, therapeutics, and vaccines. It also offers products that grant protection from ticks, fleas, and internal parasites. The Farm Animal portfolio focuses on swine, cattle, and poultry and includes an elaborate list of products. These include Denagard, Baycox, Experior, Rumensin, Monteban, Baycox, Maxiban, Comforta, Catosal, and others.
The company is strategically focused on streamlining its operations while progressing in its innovative product pipelines, demonstrating significant growth opportunities. The launch of Credelio Quattro, which is expected in Q1 2025, is expected to support the company’s position in the parasiticide segment. Furthermore, the strong performance of Experior, primarily in the heifer market, is anticipated to significantly contribute to its growth in 2025.
The potential success of such products, together with the ongoing expansion of Zenrelia – which is a JAK inhibitor for treating pruritus and atopic dermatitis in dogs launched in late September 2024 – is expected to fuel revenue growth and further strengthen Elanco Animal Health Incorporated (NYSE:ELAN)’s market position over the next few years.
8. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Year Perf: -58.78%
Analyst Upside: 65.71%
Number of Hedge Fund Holders: 35
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH).
The company’s product portfolio is helping it make significant progress towards its long-term growth, reaching key milestones such as generating continued growth in vial demand for SYFOVRE. Commercial vial demand for SYFOVRE grew by 7% quarter-over-quarter in fiscal Q3 2024. SYFOVRE also maintained its market standing with 84,500 commercial vials shipped to physicians. Net product revenue for SYFOVRE reached $152 million in fiscal Q3 2024, more than double the same period last year.
Similarly, net product revenues for EMPAVELI in the US reached approximately $24.6 million in fiscal Q3 2024. These trends reflect the potential of Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) strong product portfolio, which includes two potentially blockbuster products and a promising pipeline positioning it for long-term growth. The company ranks eighth on our list of the 12 most oversold healthcare stocks to buy now.
PGIM Jennison Health Sciences Fund stated the following regarding Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in its Q3 2024 investor letter:
“Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biotech company focusing on complement therapeutics. The company sells two drugs. The first is subcutaneous pegcetacoplan for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) which was approved in 2021. The second, approved in February 2023, is Syfovre for the treatment of Geographic Atrophy (GA). Syfovre has shown compelling data out to 36 months and its launch has been going extraordinarily well. Outside of Empaveli and Syfovre, Apellis also has a growing pipeline of complement therapeutics focused on rare disease and ophthalmology. Weakness the past several months is attributed to lack of approval of Syfovre in Europe, the launch and marketing messages of a competitive drug from Astellas Pharma named Izervay, reimbursement dynamics between the two drugs and a slower than expected growth of the overall GA market. While we believe the market opportunity for GA and that growth in the treated GA patient population is large enough to support solid growth for both drugs, we have also come to appreciate that the safety issues seen with Syfove in the Summer of 2023 have complicated the marketing message for these new drugs. This has led to slower growth in the treated GA patient population than we expected, which has led us to decrease our position in Apellis. We continue to believe in the ultimate opportunity of Syfovre but have decreased our position size to more appropriately align with our updated view of the revenue growth and peak sales potential for Syfovre.”
7. Cytokinetics, Incorporated (NASDAQ:CYTK)
Year Perf: -40.09%
Analyst Upside: 66.41%
Number of Hedge Fund Holders: 61
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company that discovers, develops, and commercializes muscle inhibitors as treatments for diseases that affect muscle performance. It develops small-molecule drug candidates particularly engineered to affect muscle function and contractility. Its clinical-stage drug candidate portfolio includes omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor.
Cytokinetics, Incorporated (NASDAQ:CYTK) is financially well-positioned. As of September 30, 2024, it has around $1.3 billion in cash and cash equivalents and investments, which supports the execution of its commercial strategies and pipeline development.
The company recently announced its ‘Vision 2030’ plan built on a strong 5-year roadmap focusing on significantly enhancing immediate and future value. A significant component of these plans is the anticipated FDA approval and commercial launch of aficamten (afi) in 2025. The launch of this leading asset holds the potential to bolster Cytokinetics, Incorporated’s (NASDAQ:CYTK) position in the hypertrophic cardiomyopathy (HCM) market. Cytokinetics, Incorporated (NASDAQ:CYTK) has plans to continue the go-to-market goals for aficamten in Germany in 2025. It also aims to expand commercial readiness activities in Europe this year to prepare for the expected approval by the European Medicines Agency (EMA) in H1 2026.
6. MoonLake Immunotherapeutics (NASDAQ:MLTX)
Year Perf: -31.74%
Analyst Upside: 84.36%
Number of Hedge Fund Holders: 27
Formerly known as Helix Acquisition Corp, MoonLake Immunotherapeutics (NASDAQ:MLTX) is a Switzerland-based clinical-stage biopharmaceutical company that develops medicines for immunologic diseases, including inflammatory skin and joint diseases. It develops tri-specific nanobody Sonelokimab (SLK), a molecule with enhanced enrichment in deep skin and joints and binding of targets that targets and penetrates difficult-to-reach inflamed tissues.
The company ended fiscal Q3 2024 with $493.9 million in cash, cash equivalents, and short-term marketable debt securities. Management expects it to support a roadmap rich in potential catalysts and a cash runway to the end of 2026. Analysts are bullish on the company’s potential due to Sonelokimab, a pipeline-in-a-product across multiple significant indications that holds the potential to be worth over $8bn in sales by 2035 across the company’s targeted indications.
MoonLake Immunotherapeutics (NASDAQ:MLTX) is investing in this growth opportunity and large clinical development programs while preparing for regulatory filings and other pre-commercial activities. Its current price target of $42.83 implies an upside of 84.36% from current levels. On January 17, analyst Richard Law, CFA, from Goldman Sachs, upgraded the rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) to a Buy and gave it an $82.00 price target.
5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Year Perf: -35.65%
Analyst Upside: 91.33%
Number of Hedge Fund Holders: 44
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops and commercializes human therapeutic drugs using antisense technology. It functions through the Ionis Core segment, which generates a pipeline of drugs through a novel drug discovery platform.
The company began a new chapter as a fully integrated commercial-stage biotechnology company with the recent launch of its first independent medicine, TRYNGOLZA, for familial chylomicronemia syndrome. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) expects three additional independent launches over the next three years, including donidalorsen later in 2025 for hereditary angioedema and olezarsen for severe hypertriglyceridemia in 2026, which is pending Phase 3 results in the second half of 2025.
Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) partners are also on track to launch four Ionis-discovered medicines over the same time period, including several that address broad patient populations. Analysts are bullish on the stock as it is continually advancing the next wave of potentially transformational wholly owned medicines, including ION582 for Angelman syndrome, which is on track to start Phase 3 development in H1 2025. The company’s strong commercial execution, recent achievements, and advancing pipeline position it to deliver growing value for stakeholders, ranking it fifth on our list.
4. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Year Perf: -30.99%
Analyst Upside: 93.22%
Number of Hedge Fund Holders: 27
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) develops medicines that treat intractable diseases by silencing the genes that cause them. Employing a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, its portfolio of therapies triggers the RNA interference (RNAi) mechanism and induces rapid, durable, and deep knockdown of target genes. The company specializes in various therapeutic domains, including liver, muscle, cardiometabolic, and central nervous system. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has around 14 clinical-stage investigational medicines, of which nine are wholly owned, and five are partnered.
The company recently closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted its first NDA for investigational plozasiran, a first-in-class investigational RNA interference (RNAi) therapeutic, which was accepted for filing by the FDA. Management says that the company is funded into 2028 and well-positioned for growth in 2025 and beyond, with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years.
Plozasiran, obesity, and the central nervous system are key value drivers fueling growth from its internal development activities in the near term. Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) obesity and CNS programs are entering early clinical studies, and the company sees emerging high-value potential in them.
3. Legend Biotech Corporation (NASDAQ:LEGN)
Year Perf: -35.32%
Analyst Upside: 113.39%
Number of Hedge Fund Holders: 31
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.
The company is rapidly building a strong product portfolio with 11 pipeline programs in hematologic malignancies, solid tumors, and autoimmune diseases. The CARVYKTI therapy for multiple myeloma proved the most successful CAR-T launch to date, drawing $334 million in net trade sales in fiscal Q4 2024.
Legend Biotech Corporation (NASDAQ:LEGN) anticipates CARVYKTI’s potential to be $5.0 billion, potentially supporting the company’s growth initiatives. It is partnering with industry leaders, such as Johnson & Johnson and Novartis, to materialize this potential and expedite the development and commercialization of its therapies. The company takes the third spot on our list of the 12 most oversold healthcare stocks to buy now.
TimesSquare Capital U.S. Focus Growth Strategy stated the following regarding Legend Biotech Corporation (NASDAQ:LEGN) in its first quarter 2024 investor letter:
“We began buying shares in Legend Biotech Corporation (NASDAQ:LEGN), a biotechnology developer of cell therapies to treat blood cancers such as multiple myeloma and leukemia. The European Union approved using Legend’s Carvykti treatment of multiple myeloma and later the FDA followed suit. Some investors may have been concerned about possible delays as Legend ramps up production, and its price declined. Though with a long-standing agreement with Johnson & Johnson and a new partnership with Novartis, we see a long runway of growth ahead, so we initiated a position.”
2. Immunovant, Inc. (NASDAQ:IMVT)
Year Perf: -44.21%
Analyst Upside: 140.76%
Number of Hedge Fund Holders: 36
Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).
The company’s primary focus is boosting the potential of its lead asset, IMVT-1402, which is rapidly progressing with six Investigational New Drug (IND) applications cleared. Its development plans for Graves’ disease also paint an optimistic picture for the company, as it does not have competition in the domain. The company’s pivotal studies in Graves’ disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) are to be conducted using standard YpsoMate® autoinjector technology and its planned commercial formulation.
As of December 31, 2024, the company’s pro forma cash balance was approximately $825 million, including around $450 million in gross proceeds from a private placement that closed on January 15, 2025. 36 hedge funds hold stakes in the company, and its median price target of $20.98 implies an upside of 140.76%.
Baron Health Care Fund stated the following regarding Immunovant, Inc. (NASDAQ:IMVT) in its first quarter 2024 investor letter:
“Somewhat offsetting the above was adverse stock selection in biotechnology and health care supplies coupled with cash exposure amid favorable market conditions. Weakness in biotechnology was mainly due to disappointing performance from Rocket Pharmaceuticals, Inc. and Immunovant, Inc. (NASDAQ:IMVT), whose shares fell double digits in the period. Immunovant is focused on autoimmune disorders targeting the FcRn mechanism of action. A host of concerns weighed on Immunovant’s stock price, the most critical of which was competitor argenx SE’s failure in pemphigus vulgaris, which has raised questions about the addressable opportunity for the FcRn class. Overall, we continue to believe FcRn will command billions in revenue and that Immunovant has one of the two competitive offerings in the space. We are most optimistic about Immunovant’s development plans in Graves’ disease, a large commercial unmet need in which they currently have no competition.”
1. CG Oncology, Inc. (NASDAQ:CGON)
Year Perf: -35.32%
Analyst Upside: 158.01%
Number of Hedge Fund Holders: 26
CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The company is making significant advancements across its pipeline to develop a potential backbone bladder-sparing therapy for NMIBC. With a strong tolerability profile and safety, cretostimogene has the potential to induce a durable, complete response in bladder cancer patients. Investors are bullish on the stock as cretostimogene’s unique product profile distinguishes it from the investigational and current NMIBC treatments.
CG Oncology, Inc. (NASDAQ:CGON) has $540.7 million in cash and cash equivalents and marketable securities as of September 30, 2024. Based on its current operating plans, management expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund operations through 2027. 26 hedge funds hold stakes in CG Oncology, Inc. (NASDAQ:CGON) as of fiscal Q3 2024. Its median price target of $27.32 implies an upside of 158.01% from current levels. On February 13, Charlie CY Yang from Bank of America Securities maintained a Buy rating on the company with a price target of $65.00.
Overall, CGON ranks first among the 12 most oversold healthcare stocks to buy now. While we acknowledge the potential of healthcare stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CGON but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
